What Is International Reference Pricing for Drugs

By Kevin Fernando · Oct 7, 2026 · 10 min read

International reference pricing is a method where one country's drug price is anchored to prices already set in other countries. A payer calculates a benchmark price from a basket of reference countries, then uses that benchmark to negotiate or set its own price. This system constrains pricing power and creates price variation across markets.

Drug prices for the same medication vary dramatically across countries. A cancer drug may cost over $100,000 more in the United States than in Germany. These differences are not random. They reflect different pricing mechanisms, negotiating power, and policy choices. One of the most common mechanisms globally is international reference pricing, a system where one country's drug price is anchored to prices already set elsewhere.

International reference pricing is now the standard approach in much of Europe and many other regions. It works by selecting a basket of reference countries, calculating a benchmark price from their publicly available drug prices, and using that benchmark to inform price negotiations or set prices in the target country. The mechanism is straightforward in concept but complex in practice, and it has profound effects on which drugs get launched where, what manufacturers charge, and what patients can access.

What international reference pricing actually is

International reference pricing is a pricing method where one country's drug price is informed by prices already negotiated in other countries. A payer in the target country identifies a set of reference countries, gathers their publicly available drug prices for the same medication, calculates a benchmark from those prices, and uses that benchmark to negotiate or set its own price.

The system creates a chain of pricing decisions. The first country to negotiate a price sets an anchor. The second country references that price. The third country may reference both, or may reference only the second. Over time, a network of reference relationships forms, and prices become linked across borders.

This is distinct from free-market pricing, where each country negotiates independently, and distinct from value-based pricing, where price reflects the clinical benefit of the drug. Reference pricing is mechanical: it says the price should be benchmarked to what others paid, regardless of whether those prices reflect true value. It is also distinct from cost-plus pricing, where a manufacturer adds a margin to production cost. Reference pricing is anchored to market transactions, not to cost.

How the reference pricing mechanism works

The reference pricing process has three steps: select the reference countries, gather their prices, and calculate the benchmark. Each step involves choices that shape the outcome.

The process begins with the target country identifying which other countries will serve as price anchors. This choice is critical because the countries selected determine the benchmark. A country that references only wealthy nations will arrive at a higher benchmark than one that includes lower-income countries. The number of reference countries included in external reference pricing baskets varied from 1 to 31 countries.

Once reference countries are selected, the target country gathers the prices those countries have already negotiated or set for the drug. These are usually public prices, obtained from health ministry databases, national pricing agencies, or published lists. The prices may be list prices or negotiated prices, depending on what data is available and what the reference pricing policy requires.

The final step is to calculate a single benchmark price from the multiple prices collected. Different countries use different calculation methods. In calculating external reference pricing, 15 countries used the average price, 7 countries used the lowest price, and 7 countries used other calculation methods. The choice of method matters: the average of high and low prices will be higher than the lowest price alone. A country that wants to constrain its own price will select the lowest-price method; a country that wants to allow higher prices will use the average.

Selecting reference countries

The choice of which countries to include in the reference basket shapes the benchmark and therefore the price the target country will pay. Countries typically select reference nations based on economic similarity, geographic proximity, or data availability. Wealthier countries with robust pricing databases are easier to reference than lower-income countries with limited public data.

In practice, this means reference baskets often include wealthy OECD nations and exclude lower-income countries. A country that selects only wealthy reference nations will benchmark to higher prices. A country that includes lower-income nations will arrive at lower benchmarks. The selection process is therefore a policy choice with real consequences: it determines whether the benchmark price will be high or low, and whether the drug will be affordable in the target country.

Calculating the reference price

Once reference countries are identified and their prices gathered, the target country applies a calculation method to derive a single benchmark. The three most common methods are average, lowest, and median.

Suppose a drug costs $100 in country A, $120 in country B, and $80 in country C. The average price is ($100 + $120 + $80) / 3, or about $100. The lowest price is $80. The median is $100. Each method produces a different benchmark, and each has different effects. The average-price method balances high and low prices. The lowest-price method creates downward pressure on all reference countries, because each knows its price will pull the benchmark down. The median method splits the difference.

Countries choose their calculation method strategically. A country that wants to constrain costs will use the lowest price. A country that wants to allow manufacturers higher margins will use the average. Among European countries using external reference pricing, the distribution of methods reflects this: 15 countries chose the average, 7 chose the lowest price, and 7 chose other approaches.

A worked example of reference pricing in practice

Imagine a new cancer drug launches in the United States at $150,000 per year. A country using external reference pricing selects a basket of reference countries and gathers their negotiated prices.

Using the average-price method, the country calculates the benchmark as the mean of the reference prices. The manufacturer knows the country will not pay significantly above the benchmark without strong justification.

Now suppose another country adds multiple countries to its reference basket, using the lowest-price method. The lowest price in the basket becomes the benchmark. This country negotiates based on that lower benchmark.

The chain continues. Each new country that references the previous ones pulls the benchmark down. The manufacturer faces a choice: accept lower prices in each successive market, or decline to launch in lower-priced countries. This is the mechanism by which reference pricing constrains prices globally, and also the mechanism by which it can delay or prevent drug launches in certain markets.

Why reference pricing matters for drug costs and access

International reference pricing reveals the pricing power of different markets and informs decisions by payers, manufacturers, and policy makers about which drugs will be available where.

For payers, reference pricing is a tool to constrain costs. By anchoring to prices already negotiated elsewhere, a payer avoids paying significantly more than others for the same drug. The system is transparent: prices are public, benchmarks are calculable, and negotiators can justify their offers by reference to what other countries paid. This reduces the manufacturer's ability to charge different prices in different markets without explanation.

For manufacturers, reference pricing creates a dilemma. A high price in one market becomes a benchmark that pulls down prices in all markets that reference it. This means the manufacturer must choose between accepting lower prices globally or declining to launch in reference-pricing countries. The decision depends on whether the lower price is still profitable given the volume of sales expected in that market.

For patients and health systems, reference pricing can improve access by lowering prices, but it can also delay access by discouraging launches. The net effect depends on the specific design of the reference pricing system and the prices in the reference countries.

How manufacturers respond to reference pricing

Manufacturers facing reference pricing systems make strategic choices about pricing, launch timing, and market entry. These choices shape which drugs are available in which countries.

One response is price tiering: charging different prices in different markets based on the reference pricing rules in each. A manufacturer might charge a high price in a country with no reference pricing and a lower price in a country that references that first price. This allows the manufacturer to capture higher margins where possible and lower margins where reference pricing constrains the price.

Another response is launch delay or non-launch. If a manufacturer expects that a reference pricing system will force the price below the level needed to generate acceptable profit, the manufacturer may choose not to launch in that country, or may delay the launch until the drug is off-patent in higher-priced markets and the lower price becomes acceptable. Within a 6-year period, manufacturers chose not to launch 11 different products to avoid expected low prices. Approximately 8% of products were withdrawn after Germany's early benefit assessment process, which drives drug pricing, likely due to prices deemed commercially unviable.

A third response is to invest in markets without reference pricing, where prices can remain higher. In 2022, U.S. manufacturer gross prices for drugs were 278 percent of prices in 33 OECD comparison countries combined. This price differential creates an incentive for manufacturers to prioritize the U.S. market and delay launches in reference-pricing countries.

Limitations and distortions of reference pricing

Reference pricing is a mechanical system, and like all mechanical systems, it produces unintended consequences. The most significant are the countries and populations excluded from the reference basket, the incentive to manipulate reference prices, and the delay or prevention of drug launches in lower-income markets.

Reference pricing creates a two-tier global market. Countries in the reference basket have access to drugs at benchmarked prices. Countries outside the basket, or countries too poor to implement reference pricing, have less negotiating power and may pay higher prices or have no access at all. This can disadvantage lower-income countries that lack the infrastructure to participate in international reference pricing systems.

Reference pricing also creates an incentive for manufacturers to manipulate the prices in reference countries. If a manufacturer knows that the price it sets in one country will become a benchmark for others, it has an incentive to set that price as high as possible to raise the global benchmark. This can distort prices in reference countries away from the true value of the drug.

The reference country selection problem

The choice of which countries to reference can distort prices in ways that harm access. If a country selects only wealthy reference nations, the benchmark will be high, and the target country will pay more. If a country selects only lower-income nations, the benchmark will be low, and manufacturers may not launch the drug in the target country because the price is unviable.

This creates a paradox: a country that wants to constrain costs by selecting low-price reference nations may end up with no access to the drug at all, because the manufacturer will not launch at the low price. A country that wants to ensure access by selecting high-price reference nations may end up paying more than necessary.

The selection problem is especially acute for lower-income countries. If they select wealthy reference nations, they inherit high prices. If they select other lower-income nations, they may have limited data and may reference countries with weak pricing power. Either way, they have less negotiating leverage than wealthy countries with robust reference pricing systems and access to high-quality pricing data.

Price referencing and launch delays

Reference pricing systems are associated with delayed drug launches. External reference pricing policies were associated with a 73% reduction in the likelihood of drug launch within 9 months of regulatory approval relative to non-reference pricing settings. This means that in countries with reference pricing, drugs take longer to reach patients after they are approved by regulators.

The delay occurs because manufacturers must first negotiate prices in reference countries, then wait for those prices to be published, then use them as benchmarks for the target country. Each step takes time. In the meantime, patients in the target country wait for access to the drug.

The delay is especially pronounced for drugs expected to have low prices in reference countries. If a manufacturer expects a low benchmark price in the target country, it may delay the launch there while prioritizing higher-priced markets. The result is that patients in reference-pricing countries may have access to new drugs years after patients in non-reference-pricing countries.

How reference pricing connects to other pricing mechanisms

International reference pricing is one of several mechanisms used to set drug prices globally. Others include value-based pricing, cost-effectiveness thresholds, and negotiated discounts. These systems often work together.

Value-based pricing is based on the principle that prices should reflect the value of a new medicine to patients, health systems, and society versus the current standard of care. Instead of referencing prices in other countries, value-based pricing uses clinical evidence to determine what the drug is worth. A drug that extends life by 2 years might be priced higher than a drug that extends life by 6 months, because the value is greater.

Cost-effectiveness thresholds are numerical benchmarks used to evaluate whether a drug's price is justified by its clinical benefit. The United Kingdom's NICE uses explicit thresholds historically about £20,000 to £30,000 per quality-adjusted life year (QALY) gained, recently raised to £25,000 to £35,000 from 2026. The United States' ICER uses $100,000 to $150,000 per QALY as benchmark thresholds, with exploration up to $200,000 per QALY for severe cases. These thresholds inform negotiations and help payers decide whether a drug's price is reasonable given its benefits.

Negotiated discounts are reductions from list price that manufacturers offer to payers in exchange for volume or market access. These discounts can be hidden or transparent, and they interact with reference pricing: a manufacturer might offer a large discount in one country to lower the reference price, or might offer a smaller discount in a reference country to keep the benchmark high.

In practice, these mechanisms overlap. A country might use reference pricing as the primary method, then apply a cost-effectiveness threshold to validate the benchmark, then negotiate discounts from the resulting price. The combination of methods creates a complex global pricing landscape where the same drug has different prices in different countries, each justified by a different mechanism.

Do this automatically

A payer manually selecting reference countries, compiling their negotiated prices, and calculating a benchmark price across multiple drugs requires significant administrative effort repeated for each new medication launch. Software systems can automate the collection of international pricing data, the selection of reference baskets, and the computation of benchmark prices, reducing the time required to complete these calculations from weeks to hours. Healthcare research reads ClinicalTrials.gov records, regulatory filings, and published literature directly, and cites each claim to the record it came from, across as many subjects as you need, with Mimir attaching a citation to every figure. It will not predict a trial's outcome or advise on anyone's treatment. Those decisions stay with clinicians and regulators, and deliberately so. Every plan includes it, including the free one.

Start your first report and run it on something you already know well.

This article is general information about healthcare and life-sciences topics. It is not medical advice, diagnosis, or treatment guidance, and it is not a substitute for a qualified professional. Any treatment decision should be discussed with a clinician.